Management of Systemic Sclerosis with Pulmonary Fibrosis

Introduction to Treatment Approach

• The American College of Rheumatology recommends mycophenolate mofetil (MMF) as the current first-line treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD), surpassing cyclophosphamide as the initial therapy of choice 1, 2

Primary Treatment Approach

• Mycophenolate mofetil (MMF) is the preferred treatment for SSc-ILD, especially in patients with anti-Scl-70 positivity, which strongly predicts ILD development and progression 3, 4, 5
• MMF is suitable for patients with stable presentation, moderate breathing restrictions, and HRCT-confirmed lower lung involvement, indicating established but manageable disease 5, 6

Why Avoid Steroids in This Case

• The European Respiratory Society notes that corticosteroid monotherapy is associated with substantial long-term morbidity in fibrotic lung disease 7, 8
• No survival benefit has been demonstrated with corticosteroids in definite pulmonary fibrosis 7
• Steroids are reserved primarily for rapidly progressive or acute exacerbation scenarios, not stable disease 9, 6

Recommended Treatment Algorithm

• The American College of Rheumatology recommends starting MMF as monotherapy for both skin and lung manifestations 5, 10, 3
• MMF addresses both skin thickening and pulmonary fibrosis simultaneously 10
• Alternative first-line option: Methotrexate if MMF is not tolerated or accessible 5, 3

Second-Line Options

• Rituximab (anti-CD20 biologic agent) can be used as a second-line option if disease progresses 5, 10, 3
• Tocilizumab (anti-IL-6 biologic agent) can be used as a second-line option if disease progresses 10, 3

Antifibrotic Therapy Addition

• Nintedanib can be added if ILD is fibrotic and progressing despite immunosuppression 5, 1, 2
• Pirfenidone is a possible alternative antifibrotic 1, 2

Evidence Supporting Steroid-Free Management

• The 2023 Nature Reviews Rheumatology guidelines state that MMF is chosen as first-line specifically because of positive benefits for ILD, even though skin score changes weren't the primary outcome in trials 5, 10
• The Scleroderma Lung Study II (SLS II) demonstrated that MMF over 2 years showed comparable efficacy to cyclophosphamide for both skin and lung manifestations 10, 3

Clinical Monitoring Strategy

• Serial pulmonary function tests (PFTs) should be performed to track forced vital capacity (FVC) 5
• Repeat HRCT imaging should be performed at defined intervals to assess fibrosis progression 5
• Monitor for disease progression indicators: worsening dyspnea, declining FVC, or HRCT changes 5, 4

Important Caveats

• Rapidly progressive ILD with acute respiratory failure requires high-dose IV methylprednisolone 9, 6
• Acute exacerbation of ILD may warrant short-term high-dose steroids 7, 8
• If steroids must be used chronically, keep doses ≤15 mg/day prednisone equivalent to minimize SRC risk
• Rituximab considerations: rare risks include pneumonitis, worsening ILD, infections, and hypogammaglobulinemia 9, 6